Skip to main content

BD Buys Sirigen

NEW YORK (GenomeWeb News) – Becton Dickinson announced today that it has acquired Sirigen, a maker of polymer dyes that are used in flow cytometry and other technologies.

Hampshire, UK-based Sirigen has developed the High Sensitivity Fluorescence detection technology with applications in the diagnostics and life science research markets. The firm's technology is platform agnostic, and according to its website, can facilitate high-volume screening for personalized medicine purposes and can be used to boost the performance of existing molecular diagnostics tests and immunoassays.

Financial terms of the deal were not disclosed. BD said that it expects the acquisition to be dilutive to its full-year 2012 earnings per share by approximately $.01 on a GAAP basis.

"This new technology is a natural complement to our instrument platforms and reagent portfolio," Alberto Mas, president of the BD Biosciences segment of BD, said in a statement. "We believe that the acquisition will enable us to develop a continuous cadence of novel, unique dyes and antibody specificity releases over the next two years, significantly expanding our life science research reagent portfolio with high-impact products."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.